Corporate calendar for Mustang Bio, Inc. (MBIO): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relap...
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-15 | ||
| 2026-09-15 | ||
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | ||
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 |
Stock Splits
| Date | Ratio |
|---|---|
| 2025-01-16 | 1:50 |
| 2023-04-04 | 1:15 |
Price
| Price | $0.50 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 1.00 |
Related companies: ABP · ACXP · BOLT · DWTX · EVGN · IMRN · LYRA
Explore sector: Healthcare · Biotechnology
More sections of MBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks